Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
NCT ID: NCT00916617
Last Updated: 2017-06-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
62 participants
INTERVENTIONAL
2009-06-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
NCT01254773
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
NCT00606476
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
NCT00663026
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
NCT00937352
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
NCT00998764
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
5 mg/week
bapineuzumab
5 mg/week subcutaneous bapineuzumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bapineuzumab
5 mg/week subcutaneous bapineuzumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Completed preceding double-blind study (3133L1-2203 US)
* MMSE score \> 9.
Exclusion Criteria
* Clinically important psychiatric symptoms
* History of stroke
50 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
INDUSTRY
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner Alzheimer's Institute
Phoenix, Arizona, United States
Pharmacology Research Institute
Encino, California, United States
Brain Matters Research
Delray Beach, Florida, United States
MD Clinical
Hallandale, Florida, United States
Palm Beach Neurology - Premiere Research Institute
West Palm Beach, Florida, United States
Neurostudies.net
Decatur, Georgia, United States
Dekalb Neurology Associates, LLC
Lawrenceville, Georgia, United States
NeuroStudies.net
Lawrenceville, Georgia, United States
Clinical Research Institute
Wichita, Kansas, United States
Monroe Community Hospital
Rochester, New York, United States
Rhode Island Mood and Memory Research Institute
East Providence, Rhode Island, United States
Butler Hospital
Providence, Rhode Island, United States
Texas Neurology, P.A.
Dallas, Texas, United States
The Memory Clinic
Bennington, Vermont, United States
University of Wisconsin, Department of Surgery
Madison, Wisconsin, United States
University of Wisconsin
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2521009
Identifier Type: OTHER
Identifier Source: secondary_id
3133L1-2204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.